Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Stocks fall ahead of UK inflation data

Tue, 12th Nov 2013 08:22

- Markets eye inflation data- BoE Inflation Report due tomorrow- Corporate earnings come in mixedtechMARK 2,636.87 -0.14%FTSE 100 6,706.83 -0.32%FTSE 250 15,395.24 -0.16%UK markets opened lower on Tuesday morning as investors refrained from building positions ahead of domestic inflation data.The figures are likely to be closely scrutinised ahead of the release of the Bank of England's November Inflation Report tomorrow along with the monthly unemployment figures.The consumer price index (CPI) is expected to have risen at an annual rate of 2.5% in October, down from 2.7% the month before and representing a six-month low."This would move us closer towards a 'safe' inflation environment where interest rates are unlikely to be raised as a result of high inflation," said Market Analyst Craig Erlam from Alpari. "Thus should we see the CPI figure come in at or below 2.5% it would likely be viewed as positive for a continuation of loose monetary policies going forward," he said. Markets give mixed response to earningsBuilding materials giant CRH gained after reporting a 2% increase in like-for-like sales in the third quarter, a strong turnaround after a 6% decline in the first half owing to difficult weather conditions. The company also hiked its target for cost savings this year after an acceleration in its ongoing spend reduction programme in Europe.Vodafone was subdued early on after the 4.9% fall in second-quarter organic revenues was slightly worse than analysts had forecast. Chief Executive Vittorio Colao admitted trading conditions in Europe remained "very tough".Land Securities edged higher after the property firm posting improved revenue profit and net asset value during the first half and saying it is confident of delivering future progress.Life insurance investment vehicle Resolution erased early losses to trade higher after a mixed third quarter, as significant growth in UK new business in the was outweighed by a more subdued performance overseas.Babcock, the engineering support services company, fell after a broadly in-line first-half report in which it lifted its dividend by 10% following a 32% jump in pre-tax profits.Meanwhile, GlaxoSmithKline fell after its heart disease drug, darapladib, missed a key milestone in its development. FTSE 100 - RisersCRH (CRH) 1,616.00p +3.66%British Sky Broadcasting Group (BSY) 844.00p +1.81%Sainsbury (J) (SBRY) 397.80p +0.96%Rexam (REX) 531.50p +0.66%Antofagasta (ANTO) 823.50p +0.61%ITV (ITV) 188.50p +0.59%Kingfisher (KGF) 388.30p +0.57%Standard Life (SL.) 346.70p +0.55%International Consolidated Airlines Group SA (CDI) (IAG) 384.80p +0.52%Aggreko (AGK) 1,580.00p +0.51%FTSE 100 - FallersFresnillo (FRES) 928.50p -2.52%Anglo American (AAL) 1,447.00p -1.83%Standard Chartered (STAN) 1,484.00p -1.62%Royal Bank of Scotland Group (RBS) 334.60p -1.53%GlaxoSmithKline (GSK) 1,628.50p -1.33%Tullow Oil (TLW) 903.50p -1.31%BG Group (BG.) 1,267.50p -1.13%Coca-Cola HBC AG (CDI) (CCH) 1,747.00p -1.13%Aberdeen Asset Management (ADN) 431.80p -1.10%Mondi (MNDI) 1,039.00p -0.95%FTSE 250 - RisersOxford Instruments (OXIG) 1,356.00p +10.51%TalkTalk Telecom Group (TALK) 265.00p +6.04%Premier Farnell (PFL) 237.80p +4.53%Bank of Georgia Holdings (BGEO) 2,089.00p +3.06%Renishaw (RSW) 1,736.00p +2.18%BTG (BTG) 432.40p +1.91%Dialight (DIA) 913.50p +1.84%Catlin Group Ltd. (CGL) 530.50p +1.24%PZ Cussons (PZC) 378.20p +1.07%Kenmare Resources (KMR) 21.33p +1.04%FTSE 250 - FallersMenzies(John) (MNZS) 772.50p -5.74%Balfour Beatty (BBY) 270.70p -4.51%Hunting (HTG) 829.00p -3.83%Polymetal International (POLY) 549.00p -3.26%Xaar (XAR) 903.50p -2.32%Evraz (EVR) 121.60p -2.17%Synthomer (SYNT) 229.00p -1.89%Rank Group (RNK) 146.50p -1.88%IP Group (IPO) 152.60p -1.86%Daejan Holdings (DJAN) 4,035.00p -1.82%BC
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.